The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 95 of 832
Back to Result List

The Role of Adjuvant Hormonal Treatment after Surgery for Localized High-Risk Prostate Cancer: Results of a Matched Multiinstitutional Analysis

Please always quote using this URN: urn:nbn:de:bvb:20-opus-137712
  • Introduction. To assess the role of adjuvant androgen deprivation therapy (ADT) in high-risk prostate cancer patients (PCa) after surgery. Materials and Methods. The analysis case matched 172 high-risk PCa patients with positive section margins or non-organ confined disease and negative lymph nodes to receive adjuvant ADT (group 1, n=86 ) or no adjuvant ADT (group 2, n=86). Results. Only 11.6% of the patients died, 2.3% PCa related. Estimated 5–10-year clinical progression-free survival was 96.9% (94.3%) for group 1 and 73.7% (67.0%) for groupIntroduction. To assess the role of adjuvant androgen deprivation therapy (ADT) in high-risk prostate cancer patients (PCa) after surgery. Materials and Methods. The analysis case matched 172 high-risk PCa patients with positive section margins or non-organ confined disease and negative lymph nodes to receive adjuvant ADT (group 1, n=86 ) or no adjuvant ADT (group 2, n=86). Results. Only 11.6% of the patients died, 2.3% PCa related. Estimated 5–10-year clinical progression-free survival was 96.9% (94.3%) for group 1 and 73.7% (67.0%) for group 2, respectively. Subgroup analysis identified men with T2/T3a tumors at low-risk and T3b margins positive disease at higher risk for progression. Conclusion. Patients with T2/T3a tumors are at low-risk for metastatic disease and cancer-related death and do not need adjuvant ADT. We identified men with T3b margin positive disease at highest risk for clinical progression. These patients benefit from immediate adjuvant ADT.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Maria Schubert, Steven Joniau, Paolo Gontero, Susanne Kneitz, Claus-Jürgen Scholz, Burkhard Kneitz, Alberto Briganti, R. Jeffery Karnes, Bertrand Tombal, Jochen Walz, Chao-Yu Hsu, Giansilvio Marchioro, Pia Bader, Chris Bangma, Detlef Frohneberg, Markus Graefen, Fritz Schröder, Paul van Cangh, Hein van Poppel, Martin Spahn
URN:urn:nbn:de:bvb:20-opus-137712
Document Type:Journal article
Faculties:Medizinische Fakultät / Urologische Klinik und Poliklinik
Language:English
Parent Title (English):Advances in Urology
Year of Completion:2012
Volume:2012
Source:Advances in Urology Volume 2012 (2012), Article ID 612707, 6 pages. DOI: 10.1155/2012/612707
DOI:https://doi.org/10.1155/2012/612707
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 617 Chirurgie und verwandte medizinische Fachrichtungen
Tag:adjuvant hormonal treatment; prostate cancer
Release Date:2016/08/25
Collections:Open-Access-Publikationsfonds / Förderzeitraum 2011
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung